Arrowhead Pharmaceuticals Stock Current Valuation
| HDP1 Stock | EUR 19.36 0.31 1.63% |
Valuation analysis of Arrowhead Pharmaceuticals helps investors to measure Arrowhead Pharmaceuticals' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Arrowhead Pharmaceuticals' price fluctuation is somewhat reliable at this time. Calculation of the real value of Arrowhead Pharmaceuticals is based on 3 months time horizon. Increasing Arrowhead Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Arrowhead stock is determined by what a typical buyer is willing to pay for full or partial control of Arrowhead Pharmaceuticals. Since Arrowhead Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Arrowhead Stock. However, Arrowhead Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 19.36 | Real 17.0 | Hype 19.36 | Naive 19.27 |
The real value of Arrowhead Stock, also known as its intrinsic value, is the underlying worth of Arrowhead Pharmaceuticals Company, which is reflected in its stock price. It is based on Arrowhead Pharmaceuticals' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Arrowhead Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Arrowhead Pharmaceuticals helps investors to forecast how Arrowhead stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Arrowhead Pharmaceuticals more accurately as focusing exclusively on Arrowhead Pharmaceuticals' fundamentals will not take into account other important factors: Arrowhead Pharmaceuticals Company Current Valuation Analysis
Arrowhead Pharmaceuticals' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Arrowhead Pharmaceuticals Current Valuation | 2.76 B |
Most of Arrowhead Pharmaceuticals' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Arrowhead Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Arrowhead Pharmaceuticals has a Current Valuation of 2.76 B. This is 80.8% lower than that of the Healthcare sector and 40.65% lower than that of the Biotechnology industry. The current valuation for all Germany stocks is 83.41% higher than that of the company.
Arrowhead Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Arrowhead Pharmaceuticals' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Arrowhead Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Arrowhead Pharmaceuticals by comparing valuation metrics of similar companies.Arrowhead Pharmaceuticals is currently under evaluation in current valuation category among its peers.
Arrowhead Fundamentals
| Return On Equity | -0.4 | |||
| Return On Asset | -0.13 | |||
| Profit Margin | (0.56) % | |||
| Operating Margin | (0.57) % | |||
| Current Valuation | 2.76 B | |||
| Shares Outstanding | 108.31 M | |||
| Shares Owned By Insiders | 4.93 % | |||
| Shares Owned By Institutions | 69.27 % | |||
| Price To Earning | 263.63 X | |||
| Price To Book | 8.32 X | |||
| Price To Sales | 13.82 X | |||
| Revenue | 243.23 M | |||
| Gross Profit | 243.23 M | |||
| EBITDA | (178.51 M) | |||
| Net Income | (176.06 M) | |||
| Cash And Equivalents | 218.2 M | |||
| Cash Per Share | 2.30 X | |||
| Debt To Equity | 2.40 % | |||
| Current Ratio | 2.31 X | |||
| Book Value Per Share | 3.55 X | |||
| Cash Flow From Operations | (136.13 M) | |||
| Earnings Per Share | (1.29) X | |||
| Target Price | 87.92 | |||
| Number Of Employees | 397 | |||
| Beta | 1.01 | |||
| Market Capitalization | 3.5 B | |||
| Total Asset | 691.94 M | |||
| Net Asset | 691.94 M |
About Arrowhead Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Arrowhead Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Arrowhead Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Arrowhead Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| EBR | Centrais Electricas Brasileiras | |
| HE | Hawaiian Electric Industries | |
| VFC | VF Corporation | |
| BVHMF | Vistry Group PLC | |
| S | SentinelOne |
Additional Information and Resources on Investing in Arrowhead Stock
When determining whether Arrowhead Pharmaceuticals is a strong investment it is important to analyze Arrowhead Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Arrowhead Pharmaceuticals' future performance. For an informed investment choice regarding Arrowhead Stock, refer to the following important reports:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Arrowhead Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in Arrowhead Stock please use our How to Invest in Arrowhead Pharmaceuticals guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.